Press release disseminated on behalf of Anatoly Langer
TORONTO, ON / ACCESSWIRE / March 26, 2014 / Dr. Anatoly Langer, control person of CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), announced that Spacibo Inc. ("Spacibo", which is the control and direction of Dr. Langer and certain of his family members) has sold 6,229,505 common shares of CardioComm Solutions in a private transaction at a price of $0.095 per share for gross proceeds of $591,802.97. The shares that were sold represent approximately 5.9% of the issued and outstanding common shares of CardioComm Solutions. The purpose of the sale of shares held in Spacibo was to enable the Langer family to convert to cash its collective interest in the Company.
Dr. Langer remains a "control person" of the Company under applicable securities laws. Personally and through holding companies including MD Primer Inc., Dr. Langer now owns or has control and direction over an aggregate of 48,258,076 common shares of CardioComm Solutions, representing approximately 45.8% of CardioComm Solutions' issued and outstanding common shares. To review the report associated with this news release, please go to CardioComm Solutions' profile on SEDAR at www.sedar.com or contact the Company at 1.800.725.6585, ext. 264.
Dr. Langer has previously purchased shares from CardioComm Solutions for investment purposes, and in the future may further purchase, hold, vote, trade, dispose or otherwise deal in the common shares of CardioComm Solutions in such manner as he deems advisable to benefit from changes in market prices of such common shares, changes in the operations of CardioComm Solutions, its business strategy or prospects or from a sale or merger of CardioComm Solutions.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Dr. Anatoly Langer
MD Primer Inc.
Dr. Anatoly Langer
To review the report associated with this news release, please go to CardioComm Solutions' profile on SEDAR at www.sedar.com or contact CardioComm Solution at 1.800.725.6585, ext. 264.
SOURCE: CardioComm Solutions, Inc.